Answers are grounded in this paper and cite their sources.
Review analyzes advancements in 1,2,3-triazole derivatives for type-2 diabetes treatment, suggesting potential therapeutic impacts.
Type-2 diabetes mellitus remains a significant global health challenge, pointing to a continuous search for more effective and selective therapeutic agents. The 1,2,3-triazole scaffolds have been highlighted as potential pharmacophores in this field over the past decade owing to their high metabolic stability, favorable electronic properties, and versatile capacity to participate in hydrogen bonding and π-stacking interactions within enzymatic binding sites. This review provides a comprehensive and critical analysis of the advancements during the last ten years in 1,2,3-triazole-based antidiabetic research in the synthesis and biological evaluation of new derivatives as potential drugs. Such new derivatives are based on compounds synthesized via copper-catalyzed azide–alkyne cycloaddition (CuAAC), a methodology which allows the synthesis of structurally diverse libraries of triazole-based targets.
No takes yet. Share an insight, caveat, or question.
Moura et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: